Cancer

Breast cancer remains the country’s most commonly diagnosed cancer, accounting for 5,822 new cases, or 16.2% of all cancers.

Researchers will use GE HealthCare’s StarGuide SPECT/CT imaging system together with MIM Software’s MIM LesionID Pro platform to monitor how tumours respond throughout treatment.

Unlike conventional open surgery, which requires large incisions in the chest and abdomen, MIE uses several small incisions, high-definition imaging, and specialized laparoscopic instruments.

The initiative will support patients with the greatest medical and financial needs by improving access to advanced therapies within a framework aligned with the UAE’s national health insurance system.

Astex will also qualify for development, regulatory, and commercial milestone payments exceeding US$465 million, totaling US$490 million with the upfront payment included.

Founded in 2019 as a spinout from Imperial College London and the Francis Crick Institute, Myricx has attracted strong investor backing and has emerged as one of the UK’s leading oncology biotechnology companies.

Verzenios is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor developed by Lilly for the treatment of several forms of breast cancer.

Unlike CAR-T therapy, which requires patient-specific cell modification and lengthy manufacturing, this treatment is delivered as a ready-to-use infusion, making it more accessible in standard hospital settings.

The decision makes satri-cel the first CAR-T therapy anywhere in the world to receive regulatory approval for a solid tumor indication.